Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 76, 2023 Sep 19.
Article
in En
| MEDLINE
| ID: mdl-37726304
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
NPJ Breast Cancer
Year:
2023
Document type:
Article